Abstract：
BACKGROUND: Ulcerative colitis (UC) is a chronic inflammatory disease of the colon. Ginsenoside may be an ideal agent for UC treatment. However, its efficacy and safety are unknown. We aim to conduct a systematic evaluation to assess the effects and potential mechanisms of ginsenosides in animal models of UC.
METHODS: Six electronic databases will be searched (PubMed, Embase, Web of Science, China Knowledge Network (CNKI), China Science and Technology Journal Database (CQVIP), and Wanfang Data Knowledge). SYRCLE list will be used to assess the quality of literature, and STATA 15.1 for data analysis. Time-dose effects analysis will be used to reveal the time-dosage response relations between ginsenosides and UC.
RESULTS: Ultimately, fifteen studies involving 300 animals were included. Preliminary evidence was shown that ginsenosides could reduce Disease Activity Index (DAI) scores, weight loss, histological colitis score (HCS), spleen weight, Malondialdehyde (MDA), Myeloperoxidase (MPO) activity, interleukin-1β (IL-1β), interleukin 6 (IL-6), tumor necrosis factor α (TNF-α) and increase colon length (CL), myeloperoxidase (GSH), interleukin 4 (IL-4), interleukin 10 (IL-10), Zonula Occludens-1 (ZO-1) and occludin. Results of time-dose interval analysis indicated that ginsenosides at a dosage of 5-200 mg/kg with an intervention time of 7-28 days were relatively effective.
CONCLUSIONS: Preclinical evidence suggests that ginsenoside is a novel treatment for UC. And the mechanisms of ginsenosides in treating UC may involve anti-inflammatory, antioxidant, barrier protection, intestinal flora regulation, and immune regulation. Although, due to the high heterogeneity, further large-scale and high-quality preclinical studies are needed to examine the protection of ginsenosides against UC.
METHODS: Six electronic databases will be searched (PubMed, Embase, Web of Science, China Knowledge Network (CNKI), China Science and Technology Journal Database (CQVIP), and Wanfang Data Knowledge). SYRCLE list will be used to assess the quality of literature, and STATA 15.1 for data analysis. Time-dose effects analysis will be used to reveal the time-dosage response relations between ginsenosides and UC.
RESULTS: Ultimately, fifteen studies involving 300 animals were included. Preliminary evidence was shown that ginsenosides could reduce Disease Activity Index (DAI) scores, weight loss, histological colitis score (HCS), spleen weight, Malondialdehyde (MDA), Myeloperoxidase (MPO) activity, interleukin-1β (IL-1β), interleukin 6 (IL-6), tumor necrosis factor α (TNF-α) and increase colon length (CL), myeloperoxidase (GSH), interleukin 4 (IL-4), interleukin 10 (IL-10), Zonula Occludens-1 (ZO-1) and occludin. Results of time-dose interval analysis indicated that ginsenosides at a dosage of 5-200 mg/kg with an intervention time of 7-28 days were relatively effective.
CONCLUSIONS: Preclinical evidence suggests that ginsenoside is a novel treatment for UC. And the mechanisms of ginsenosides in treating UC may involve anti-inflammatory, antioxidant, barrier protection, intestinal flora regulation, and immune regulation. Although, due to the high heterogeneity, further large-scale and high-quality preclinical studies are needed to examine the protection of ginsenosides against UC.
摘要：
背景：溃疡性结肠炎（UC）是一种慢性结肠炎性疾病。人参皂苷可能是治疗UC的理想药物。然而,其疗效和安全性尚不清楚。我们旨在进行系统评价，以评估人参皂苷在UC动物模型中的作用和潜在机制。
方法：将搜索六个电子数据库(PubMed，Embase,WebofScience,中国知网(CNKI),中国科技期刊数据库(CQVIP),和万方数据知识)。系统列表将用于评估文献质量，和STATA15.1用于数据分析。时间-剂量效应分析将用于揭示人参皂苷与UC之间的时间-剂量反应关系。
结果：最终，纳入了涉及300只动物的15项研究.初步证据表明，人参皂苷可以降低疾病活动指数（DAI）评分，减肥,组织学结肠炎评分（HCS），脾脏重量,丙二醛(MDA),髓过氧化物酶(MPO)活性,白细胞介素-1β（IL-1β），白细胞介素6（IL-6），肿瘤坏死因子α（TNF-α）和增加结肠长度（CL），髓过氧化物酶（GSH），白细胞介素4（IL-4），白细胞介素10（IL-10），ZonulaOccludens-1（ZO-1）和occludin。时间-剂量间隔分析结果表明，人参皂苷的剂量为5-200mg/kg，干预时间为7-28天相对有效。
结论：临床前证据表明人参皂苷是治疗UC的一种新方法。人参皂苷治疗UC的作用机制可能涉及抗炎,抗氧化剂，屏障保护,肠道菌群调节，和免疫调节。虽然,由于高度的异质性，需要进一步的大规模和高质量的临床前研究来检查人参皂苷对UC的保护作用。
方法：将搜索六个电子数据库(PubMed，Embase,WebofScience,中国知网(CNKI),中国科技期刊数据库(CQVIP),和万方数据知识)。系统列表将用于评估文献质量，和STATA15.1用于数据分析。时间-剂量效应分析将用于揭示人参皂苷与UC之间的时间-剂量反应关系。
结果：最终，纳入了涉及300只动物的15项研究.初步证据表明，人参皂苷可以降低疾病活动指数（DAI）评分，减肥,组织学结肠炎评分（HCS），脾脏重量,丙二醛(MDA),髓过氧化物酶(MPO)活性,白细胞介素-1β（IL-1β），白细胞介素6（IL-6），肿瘤坏死因子α（TNF-α）和增加结肠长度（CL），髓过氧化物酶（GSH），白细胞介素4（IL-4），白细胞介素10（IL-10），ZonulaOccludens-1（ZO-1）和occludin。时间-剂量间隔分析结果表明，人参皂苷的剂量为5-200mg/kg，干预时间为7-28天相对有效。
结论：临床前证据表明人参皂苷是治疗UC的一种新方法。人参皂苷治疗UC的作用机制可能涉及抗炎,抗氧化剂，屏障保护,肠道菌群调节，和免疫调节。虽然,由于高度的异质性，需要进一步的大规模和高质量的临床前研究来检查人参皂苷对UC的保护作用。
